UK government to examine AI's role in clinical trials
The House of Lords Science and Technology Committee will investigate how artificial intelligence can speed up clinical trials and personalized medicine delivery across the NHS. The inquiry, launched this month, sits within the Labour government's broader AI for science strategy.
The committee will focus on gaps between early-stage research, clinical trials, and NHS-wide implementation. It will examine what slows progress: procurement processes, clinical pathways, and the role of regulators and professional bodies.
Lord Mair, the committee chair, said the inquiry will "seek to establish the state of the science and technology in this area and understand where patients might benefit from near-term developments."
Government targets 100-day drug development by 2030
The government aims to use AI to develop trial-ready drugs within 100 days by 2030. The target reflects a push to make the UK more competitive for clinical trial sites.
The UK has already cut trial approval times significantly. The Medicines and Healthcare products Regulatory Agency halved the average approval period from 91 days to 41 days following digital reforms backed by AI technology.
AI already supporting neurodegenerative research
The government-backed IXI Brain Atlas project demonstrates AI's current application. The project builds a model to identify neurodegenerative disorders and is supporting more than 40 clinical trials into diseases like Alzheimer's by analyzing brain scans.
For government professionals involved in health policy, regulation, or procurement, understanding these developments matters. The inquiry will identify where systems need to change to move AI-backed treatments from research to patients faster.
Learn more about AI for Healthcare and AI for Government.
Your membership also unlocks:
